EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia

Ramya Nair, Alejandro Salinas-Illarena, Monika Sponheimer, Inès Wullkopf, Yannick Schreiber, João Vasco Côrte-Real, Augusto Del Pozo Ben, Helena Marterer, Dominique Thomas, Gerd Geisslinger, Jindrich Cinatl, Marion Subklewe und 1 weitere

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01425-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Ramya Nair und 12 weiteren Autor:innen. Beteiligte Einrichtung: Max Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Feodor-Lynen-S…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung, Fundação para a Ciência e Tecnologia, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Knowledge of the molecular pathogenesis of acute myeloid leukemia has advanced in recent years. Despite novel treatment options, acute myeloid leukemia remains a survival challenge for elderly patients. We have recently shown that the triphosphohydrolase SAMHD1 is one of the factors determining resistance to Ara-C treatment. Here, we designed and tested novel and simpler virus-like particles incorporating the lentiviral protein Vpx to efficiently and transiently degrade SAMHD1 and increase the efficacy of Ara-C treatment. The addition of minute amounts of lentiviral Rev protein during production enhanced the generation of virus-like particles. In addition, we found that our 2nd generation of virus-like particles efficiently targeted and degraded SAMHD1 in AML cell lines with high levels of SAMHD1, thereby increasing Ara-CTP levels and response to Ara-C treatment. Primary AML blasts were generally less responsive to VLP treatment. In summary, we have been able to generate novel and simpler virus-like particles that can efficiently deliver Vpx to target cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteCytarabineHumansSAM Domain and HD Domain-Containing Protein 1Viral Regulatory and Accessory ProteinsCell Line, TumorLentivirus

Stichwörter der Autor:innen

AMLCytarabineResistanceSAMHD1VLPVpx

Substanzen

CytarabineSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanViral Regulatory and Accessory ProteinsVPX protein, Human immunodeficiency virus 2

Autor:innen und Institutionen

  • Max Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Feodor-Lynen-Str. 23, 81377, Munich, Germany.
  • Department of Medicine III, University Hospital, LMU, Munich, Germany.
  • Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60596, Frankfurt Am Main, Germany.
  • CIBIO-InBIO, Research Center in Biodiversity and Genetic Resources, University of Porto, 4485-661, Vairão, Portugal.
  • Department of Biology, Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal.

Förderung

  • Wilhelm Sander-Stiftung
  • Fundação para a Ciência e Tecnologia
  • Deutsche Forschungsgemeinschaft
  • Studienstiftung des deutschen Volkes
  • Joachim Herz Foundation
  • Bavarian Elite Graduate School “i-target”
  • Fraunhofer Cluster of Excellence for Immune mediated Diseases
  • Ludwig-Maximilians-Universität München

Zitieren

APA

Nair, R., Salinas-Illarena, A., Sponheimer, M., Wullkopf, I., Schreiber, Y., Côrte-Real, J. V., Del Pozo Ben, A., Marterer, H., Thomas, D., Geisslinger, G., Cinatl, J., Subklewe, M., & Baldauf, H. M. (2024). Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01425-w

Vancouver

Nair R, Salinas-Illarena A, Sponheimer M, Wullkopf I, Schreiber Y, Côrte-Real JV, et al. Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01425-w

BibTeX
@article{Nair2024,
  author = {Nair, Ramya and Salinas-Illarena, Alejandro and Sponheimer, Monika and Wullkopf, Inès and Schreiber, Yannick and Côrte-Real, João Vasco and Del Pozo Ben, Augusto and Marterer, Helena and Thomas, Dominique and Geisslinger, Gerd and Cinatl, Jindrich and Subklewe, Marion and Baldauf, Hanna-Mari},
  title = {Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01425-w}
}
Kostenlos starten →